GOVX - GeoVax Labs, Inc.

NasdaqCM - NasdaqCM Real-time price. Currency in USD
0.6090
-0.0244 (-3.85%)
At close: 03:59PM EDT
0.4999 -0.11 (-17.91%)
After hours: 07:59PM EDT
Stock chart is not supported by your current browser
Previous close0.6334
Open0.6400
Bid0.4810 x 800
Ask0.5000 x 1100
Day's range0.5952 - 0.6534
52-week range0.5310 - 4.3000
Volume579,038
Avg. volume297,488
Market cap16.104M
Beta (5Y monthly)3.00
PE ratio (TTM)N/A
EPS (TTM)-0.6300
Earnings date01 Aug 2023 - 07 Aug 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est5.40
  • GlobeNewswire

    GeoVax Partners With ABL to Advance cGMP Production of Vaccine Candidates

    ATLANTA, GA, May 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced it has executed a Master Services Agreement (MSA) with Advanced Bioscience Laboratories, Inc. (ABL) to support current Good Manufacturing Practices (cGMP) production of the company’s vaccine candidates, including GEO-MVA and GEO-CM04S1. ABL, a subsidiary of Institut Mérieux, is a

  • GlobeNewswire

    GeoVax to Participate in Upcoming Industry Meetings

    Management to participate in 2023 ASCO Annual Meeting and 2023 BIO International Convention ATLANTA, GA, May 25, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, announced today that its Chief Medical Officer, Kelly T. McKee, M.D., will participate in the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting, in Chicago on June 2-6, 2023, and its Chairman and CEO

  • GlobeNewswire

    GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients

    New and Unpublished Data from Phase 2 Open-Label Safety Study ofGEO-CM04S1 Presented at Two Recent Scientific Meetings ATLANTA, GA, May 24, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today the presentation of updates on the development of its next-generation SARS-CoV-2 vaccine, GEO-CM04S1, including preliminary data from an ongoing Phase 2 clinical

  • GlobeNewswire

    GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings

    Presentations to Include New and Unpublished Data from Phase 2 Open-Label Safety Study of GEO-CM04S1 ATLANTA, GA, May 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it will be represented during two upcoming scientific meetings, including Vaccines Summit Boston 2023 in Boston, MA, May 22-24, 2023 and CYTO 2023 in Montréal, Québec, Canada

  • GlobeNewswire

    GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference

    ATLANTA, GA, May 09, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it will participate in the Alliance Global Partners’ Virtual Healthcare Conference being held May 23-24, 2023. During the event, the GeoVax management team will be conducting one-on-one investor meetings. To request a meeting with management please contact your appropriate A

  • GlobeNewswire

    GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update

    Cancer Gene Therapy Program and Next-Generation COVID-19 VaccineAdvancing in Phase 2 Clinical Trials Company to Host Conference Call and Webcast Today at 4:30 p.m. ET ATLANTA, GA, May 04, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire– GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing vaccines and immunotherapies against cancers and infectious diseases, today announced its financial results for the three months ended March 31, 2023, and recent corporate highlights. GeoVax’s leaders

  • GlobeNewswire

    GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host

    ATLANTA, GA, April 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing vaccines and immunotherapies against cancers and infectious diseases, today announced its participation in and sponsor support of the 4th Symposium on Infectious Diseases in the Immunocompromised Host, being held April 30 to May 2, 2023, in Seattle, Washington and hosted by the Fred Hutchinson Cancer Center. Medical leadership representation from GeoVax will att

  • GlobeNewswire

    GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023

    ATLANTA, GA, April 25, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, announced today that it will report first quarter 2023 financial results on Thursday, May 4, 2023, after the market closes. Following the release, management will host a live conference call and webcast to provide a general business update and discuss financial results. Subsequen

  • GlobeNewswire

    GeoVax Announces Expansion of Next-Generation COVID-19 Vaccine Rights to Include Omicron Variants and Use Against Orthopoxviruses

    Expanded Rights Include Development of GEO-CM04S1 Against Mpox (Monkeypox) and Smallpox ATLANTA, GA, April 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the expansion of its rights under its exclusive license agreement with City of Hope (COH), a world-renowned cancer research and treatment organization, to include development and commercial

  • GlobeNewswire

    GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate

    Analysis of Open-Label Portion of Ongoing Phase 2 Trial of GEO-CM04S1 Presented at 23rd Annual World Vaccine Congress Atlanta, GA, April 06, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, presented an update on the development of its SARS-CoV-2 vaccine, GEO-CM04S1, including preliminary data from an ongoing Phase 2 clinical trial, during the 23rd Annual World Va

  • GlobeNewswire

    GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress

    80% Survival in Nonhuman Primates Observed in a Lethal Challenge Model Atlanta, GA, April 05, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the presentation of encouraging data from recent nonhuman primate studies of GeoVax’s vaccine candidate (GEO-MM01) against Marburg virus, during the 23rd Annual World Vaccine Congress taking place in Washing

  • GlobeNewswire

    GeoVax to Participate at the World Vaccine Congress with Multiple Presentations

    New data from the ongoing Phase 2 trial of GEO-CM04S1 to be presented Atlanta, GA, March 30, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it will be represented in two presentations during the upcoming 23rd Annual World Vaccine Congress taking place in Washington, DC on April 3-6, 2023. Presentation Details · On Wednesday, April 5, during

  • GlobeNewswire

    GeoVax Reports 2022 Year-End Financial Results and Provides Corporate Update

    Company Expands Ongoing Clinical Trials and theBreadth and Capacity of Its Novel Vaccine Platform Technology ATLANTA, GA, March 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced its financial results and key operational accomplishments for the year ended December 31, 2022. GeoVax’s leadership will host a live conference call and webcast at 4:30

  • GlobeNewswire

    GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress

    Dr. Diamond and City of Hope COVID-19 Vaccine Team Nominated forBest Academic/Research Team Award ATLANTA, GA, March 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against solid tumor cancers and infectious diseases, today congratulates its colleague and collaborator, Don Diamond, Ph.D. for recognition as a finalist for the Best Academic/Research Team Award, part of the Vaccine Industry Excellence

  • GlobeNewswire

    GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update

    Conference call to be held Thursday, March 23, at 4:30 p.m. Eastern Time ATLANTA, GA, March 09, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, announced today that it will report 2022 financial results on Thursday, March 23, 2023 after the market closes. Following the release, management will host a live conference call and webcast to provide a gen

  • GlobeNewswire

    GeoVax to Participate at the 35th Annual Roth Conference

    Company Progress to be Discussed During Analyst-Led Fireside Chat ATLANTA, GA, March 06, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that its Chairman and CEO, David Dodd, will discuss the company’s progress with Senior Research Analyst Kumaragura Raja, Ph.D. from ROTH MKM. The discussion will take place during a fireside chat at the 35th Ann

  • GlobeNewswire

    GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections

    Data Presented Indicated Very High Levels of Immunogenicity of the Combinational Therapy ATLANTA, GA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the presentation of results from a clinical study of a combinational HIV therapy that included GeoVax’s HIV vaccine candidate, MVA62B. The data were presented at the Conference on Retroviru

  • GlobeNewswire

    GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial

    Mobile Community Clinical Research Facility to be Deployed in California ATLANTA, GA, Feb. 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, and EmVenio Research, a patient-focused decentralized trial global organization, today announced a collaboration to deploy a mobile clinical facility in the Claremont, California area to expand GeoVax’s ongoing Phase 2 cli

  • GlobeNewswire

    GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines

    Focused on Providing Rapid Response to Combat Emerging Infectious Threats ATLANTA, GA, Feb. 08, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced significant progress in developing a high-yield, high-capacity, continuous avian cell line system for manufacturing its MVA (modified vaccinia Ankara)-based vaccines and immunotherapies. Currently, MVA vac

  • GlobeNewswire

    GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers

    Phase 1/2 Trial Now Active at Stanford, Emory, and Thomas Jefferson Universities ATLANTA, GA, Feb. 07, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today its clinical trial of Gedeptin® for patients with recurrent head and neck cancers is now actively enrolling patients at three major research centers -- Stanford University, Emory University and Thom

  • GlobeNewswire

    GeoVax to Present at the 2023 BIO CEO & Investor Conference

    ATLANTA, GA, Jan. 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that its Chairman and CEO, David Dodd, will present at the 2023 BIO CEO & Investor Conference taking place in-person in New York City at the New York Marriott Marquis and virtually on February 6-9, 2023. BIO CEO & Investor Conference Date: Tuesday, February 7, 2023 Time: 3:45 PM

  • GlobeNewswire

    GeoVax Receives Notice of Allowance for Zika Vaccine Patent

    Preclinical Evaluation Demonstrated 100% Protection Against a Lethal Dose of Zika Virus ATLANTA, GA, Jan. 25, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that the U.S. Patent and Trademark Office issued a Notice of Allowance for Patent Application No. 17/000,768 titled, “Method for Generating a ZIKV Immune Response Utilizing a Recombinant Mod

  • GlobeNewswire

    GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023

    ATLANTA, GA, Jan. 04, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that it will present at the Biotech Showcase coinciding with the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, January 9-12, 2023. Presentation Details: Presenter: David Dodd, Chairman & CEO Date/Time: January 9, 2023, 5:00 pm PST Location: Hilton Union Square,

  • GlobeNewswire

    Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax

    First Woman President and CEO of MSM and Internationally Recognized Health Equity Advocate Joins in GeoVax Special Advisory Role ATLANTA, GA, Dec. 20, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today the appointment of Valerie Montgomery Rice, MD, FACOG, Morehouse School of Medicine President and CEO, as Special Advisor to the Chairman/CEO and Boa

  • GlobeNewswire

    GeoVax Appoints Jayne Morgan, M.D., to its Board of Directors

    Dr. Morgan Brings Extensive COVID-19, Medical and Healthcare Management Expertise ATLANTA, GA, Dec. 07, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that it has appointed Jayne Morgan, M.D., to its Board of Directors. Dr. Morgan is an accomplished and forward-thinking healthcare management executive and research leader with extensive expertise